On December 1, 2020 Dova Pharmaceuticals, Inc., a wholly-owned subsidiary of Swedish Orphan Biovitrum AB (publ) (Sobi), reported that data on DOPTELET (avatrombopag), an oral thrombopoietin receptor agonist (TPO-RA) for the treatment of chronic immune thrombocytopenia (ITP), will be presented at the 62nd American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting being held as a virtual event, December 5-8, 2020 (Press release, Dova Pharmaceuticals, DEC 1, 2020, View Source [SID1234572065]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We look forward to presenting data that reinforce the positive efficacy and safety profile of DOPTELET in patients with ITP at the 2020 ASH (Free ASH Whitepaper) annual meeting," said Michael Vredenburg, Ph.D., Head of Medical Affairs at Dova. "Specifically, these presentations will provide additional insight into the efficacy and durability of platelet response with DOPTELET treatment in patients suffering from chronic ITP, as well as show new safety and efficacy analyses from the ITP clinical development program."

Poster Presentation Details:

Poster #835: Consistent Efficacy Demonstrated by Avatrombopag in Immune Thrombocytopenia (ITP) Regardless of the Number of Lines of Prior ITP Treatment
Session: 311: Disorders of Platelet Number of Function
Presentation Date: Saturday, December 5, 7:00 am-3:30 pm
Poster #844: Characterization of Thromboembolic Events Occurring During the Avatrombopag Immune Thrombocytopenia (ITP) Clinical Development Program
Session: 311: Disorders of Platelet Number of Function
Presentation Date: Saturday, December 5, 7:00 am-3:30 pm
Poster #2675: Durability of Initial Platelet Count Response in Patients Treated with Avatrombopag for Immune Thrombocytopenia (ITP): Post-hoc Results from a Phase 3 Clinical Study
Session: 311: Disorders of Platelet Number of Function
Presentation Date: Monday, December 7, 7:00 am-3:30 pm
About DOPTELET (avatrombopag)

DOPTELET is an oral thrombopoietin (TPO) receptor agonist administered with food. DOPTELET is approved by both the FDA and EMA for the treatment of thrombocytopenia (low platelet counts) in adult patients with chronic liver disease (CLD) who are scheduled to undergo a procedure. In June 2019, DOPTELET was approved by the FDA for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.

Full prescribing information for DOPTELET is available at www.Dova.com.

Important Safety Information

In patients with chronic liver disease, the most common adverse reactions (≥ 3%) were pyrexia, abdominal pain, nausea, headache, fatigue, and edema peripheral.

In patients with chronic immune thrombocytopenia, the most common adverse reactions (≥ 10%) were headache, fatigue, contusion, epistaxis, upper respiratory tract infection, arthralgia, gingival bleeding, petechiae and nasopharyngitis.